1
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      MET Amplification (MET/CEP7 Ratio ≥ 1.8) Is an Independent Poor Prognostic Marker in Patients With Treatment-naive Non-Small-cell Lung Cancer.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The MET pathway is a promising target in patients with non-small-cell lung cancer (NSCLC). Fluorescence in situ hybridization analysis has become a standard method to detect MET amplification. However, no consensus has been reached regarding the definition of MET amplification. We aimed to find clinically meaningful cutoffs for MET amplification that could be used as a prognostic marker and/or indication for MET inhibitor therapy.

          Related collections

          Author and article information

          Journal
          Clin Lung Cancer
          Clinical lung cancer
          Elsevier BV
          1938-0690
          1525-7304
          July 2021
          : 22
          : 4
          Affiliations
          [1 ] Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX; Department of Thoracic Surgery, The Second Xiangya Hospital of Central South University, Changsha, China.
          [2 ] Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX.
          [3 ] Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX.
          [4 ] Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX. Electronic address: gtang@mdanderson.org.
          Article
          S1525-7304(20)30335-1
          10.1016/j.cllc.2020.11.002
          33288441
          bb5f820d-1cb3-4c31-9670-f491c9769b4b
          History

          FISH analysis,MET,MET inhibitor,NSCLC,Survival,pathway
          FISH analysis, MET, MET inhibitor, NSCLC, Survival, pathway

          Comments

          Comment on this article